Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

A novel class of small-molecule inhibitors targeting bacteriophage infection

Veröffentlichungen: Beitrag in Fachzeitschrift › Artikel › Peer Reviewed

Abstract

Bacteriophages have emerged as important factors in human health and disease, with elevated phage levels associated with exacerbated inflammatory bowel disease, type 2 diabetes and poor outcomes in skin and lung infections. The mechanisms linking phages to these pathologies remain largely unknown, partly because specific chemical tools inhibiting bacteriophage replication (phage blockers) are lacking. Here, we identify benzimidazylpyrazoles as novel bacteriophage antivirals. Unlike existing synthetic antiphage compounds benzimidazylpyrazoles do not intercalate DNA and target an early stage of phage infection after adsorption. An optimized derivative reduced phage titer up to 105-fold and demonstrated activity against different phage morphotypes and bacterial hosts, establishing it as a valuable chemical tool for the study of disease-related phage-host interactions.

OriginalspracheEnglisch
Seiten (von - bis)31-37
Seitenumfang7
FachzeitschriftRSC Chemical Biology
Jahrgang7
Ausgabenummer1
DOIs
PublikationsstatusVeröffentlicht - 1 Jan. 2026

Fördermittel

This work was funded by an ERC Consolidator Grant of the European Research Council under the European Union's Horizon 2020 Research and Innovation Program (Grant 865849-CAPSID). We also acknowledge funding from the Austrian Science Fund (FWF) [ https://doi.org/10.55776/COE7 ]. For open access purposes, the author has applied a CC BY public copyright license to any author accepted manuscript version arising from this submission. We acknowledge the NMR centre of the Faculty of Chemistry and the NMR facility at the Department of Pharmaceutical Sciences, Faculty of Life Sciences, University of Vienna, for providing critical support and access to instrumentation for this work. We are grateful to Joseph Bondy-Denomy (UCSD) for sharing Pseudomonas phages and strains with us.

TrägerTrägernummer
Fonds zur Förderung der wissenschaftlichen Forschung (FWF)doi.org/10.55776/COE7
European Research CouncilERC COG Grant 865849-CAPSID

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

ÖFOS 2012

  • 104004 Chemische Biologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „A novel class of small-molecule inhibitors targeting bacteriophage infection“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitationsweisen